Long-term follow-up of three prospective randomized trials comparing different antibody induction protocols

2002 ◽  
Vol 21 (1) ◽  
pp. 167-168
Author(s):  
A Zuckermann ◽  
D Dunkler ◽  
M Czerny ◽  
J Ankersmit ◽  
C Holzinger ◽  
...  
Keyword(s):  
Randomized Trials ◽  
Long Term Follow Up ◽  
Antibody Induction

Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction

2006 ◽  
Vol 96 (12) ◽  
pp. 700-710 ◽  
Author(s):  
Harry Suryapranata ◽  
Massimo Chiariello ◽  
Giuseppe De Luca
Keyword(s):  
Randomized Trials ◽  
Scientific Session ◽  
Primary Angioplasty ◽  
Review Literature ◽  
Distal Embolization ◽  
Early Administration ◽  
Long Term Follow Up ◽  
Mechanical Devices

SummaryDistal embolization is a relatively common complication in primary angioplasty and is associated with poor perfusion and higher mortality. The aim of this article is to critically review literature on pharmacological and mechanical therapies to prevent distal embolization in patients undergoing primary angioplasty. The literature was scanned by formal searches of electronic databases (MEDLINE, Pubmed) from January 1990 to March 2006 and scientific session abstracts (from January 1990 to March 2006) and oral presentation and/or expert slide presentations (from January 2002 to March 2006) (on TCT, AHA, ESC, ACC and EuroPCR websites). No language restrictions were enforced. Several pharmacological and mechanical therapies have been investigated to prevent distal embolization.Abciximab has been shown to reduce mortality,and its early admin-istration may provide additional benefits in outcome due to improvement in preprocedural reperfusion.The results of randomized trials on adjunctive mechanical devices remain controversial. Even though they reduce distal embolization and improve myocardial perfusion, no benefits have been observed in terms of 30-day survival. Adjunctive abciximab has improved survival, and its early administration is to be recommended, particularly when transportation to a primary PCI center is needed. Pending the results of large randomized trials with long-term follow-up data, the routine use of adjunctive mechanical devices to prevent distal embolization cannot be recommended, though selective use of these devices might be considered when large thrombotic burden is present.

What is the Correct Period of Bandaging following Sclerotherapy?

1986 ◽  
Vol 1 (3) ◽  
pp. 217-220 ◽  
Author(s):  
P. Reddy ◽  
J. Wickers ◽  
T. Terry ◽  
P. Lamont ◽  
J. Moller ◽  
...  
Keyword(s):  
Scoring System ◽  
Randomized Trials ◽  
Varicose Veins ◽  
Objective Assessment ◽  
Injection Sclerotherapy ◽  
Additional Advantage ◽  
Long Term Follow Up ◽  
Primary Varicose Veins

Two consecutive randomized trials following injection sclerotherapy for varicose veins compared 3 and 6 weeks bandaging in 148 patients and 1 to 3 weeks bandaging in 130 patients. Objective assessment and patient's symptoms, using a scoring system, correlated well and showed that there was no difference whatsoever between 3 and 6 weeks' bandaging after a 6 year follow-up. In the second trial, the patients who were bandaged for 3 weeks were significantly better (P < 0.001) than after only one week of bandaging at a maximum follow up of 4 years. Long term follow up of injection sclerotherapy for primary varicose veins suggests that 3 weeks is superior to 1 week bandaging, but that there is no additional advantage in continuing bandaging for six weeks.

Clinical outcome after surgical clipping or endovascular coiling for cerebral aneurysms: a pragmatic meta-analysis of randomized and non-randomized trials with short- and long-term follow-up

2016 ◽  
Vol 9 (3) ◽  
pp. 264-277 ◽  
Author(s):  
Alberto Falk Delgado ◽  
Tommy Andersson ◽  
Anna Falk Delgado
Keyword(s):  
Clinical Outcome ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Lower Mortality ◽  
Controlled Trials ◽  
Short Term ◽  
Unruptured Aneurysms ◽  
Long Term Follow Up

BackgroundTwo randomized trials have evaluated clipping and coiling in patients with ruptured aneurysms. Aggregated evidence for management of ruptured and unruptured aneurysms is missing.ObjectiveTo conduct a meta-analysis evaluating clinical outcome after aneurysm treatment.MethodsPubMed, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov were searched for studies evaluating aneurysm treatment. The primary outcome measure was an independent clinical outcome (modified Rankin scale 0–2, Glasgow Outcome Scale 4–5, or equivalent). Secondary outcomes were poor outcome and mortality. ORs were calculated on an intention-to-treat basis with 95% CIs. Outcome heterogeneity was evaluated with Cochrane's Q test (significance level cut-off value at <0.10) and I2(significance cut-off value >50%) with the Mantel–Haenszel method for dichotomous outcomes. A p value <0.05 was regarded as statistically significant.ResultsSearches yielded 18 802 articles. All titles were assessed, 403 abstracts were evaluated, and 183 full-text articles were read. One-hundred and fifty articles were qualitatively assessed and 85 articles were included in the meta-analysis. Patients treated with coiling (randomized controlled trials (RCTs)) had higher independent outcome at short-term follow-up (OR=0.67, 95% CI 0.57 to 0.79). Independent outcome was favored for coiling at intermediate and long-term follow-up (RCTs and observational studies combined—OR=0.80, 0.68 to 0.94 and OR=0.81, 0.71 to 0.93, respectively). Independent outcome and lower mortality was favored after coiling in unruptured aneurysms (database registry studies) at short-term follow-up (OR=0.34, 0.29 to 0.41 and OR=1.74, 1.52 to 1.98, respectively).ConclusionsThis meta-analysis evaluating clinical outcome after coiling or clipping for intracranial aneurysms, indicates a higher independent outcome and lower mortality after coiling.

Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

Cancer ◽  
1997 ◽  
Vol 80 (S11) ◽  
pp. 2181-2185 ◽  
Author(s):  
Ellin Berman ◽  
Peter Wiernik ◽  
Ralph Vogler ◽  
Enrique V�lez-G�rcia ◽  
Alfred Bartolucci ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Randomized Trials ◽  
Long Term Follow Up ◽  
Acute Myeloid

Abstract 1998: Short- and Long-Term Effects of Abciximab in Patients Undergoing Primary Stenting for Acute Myocardial Infarction: Meta-Analysis of Randomized Trials

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Sujethra Vasu ◽  
Gregg W Stone ◽  
David L Brown
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Randomized Trials ◽  
No Reduction ◽  
Meta Analysis ◽  
Long Term Follow Up ◽  
Primary Stenting ◽  
Short And Long Term

Background: Both short- and long-term benefits of abciximab therapy in primary angioplasty for acute myocardial infarction (AMI) have been reported. However, primary stenting is the preferred treatment of AMI and conflicting data exists on the effect of abciximab therapy on outcomes following primary stent treatment of AMI. We therefore performed a meta-analysis of all randomized trials of abciximab in primary stenting for AMI for which there was short-term (30-day) and long-term (≥ 1 year) follow-up. Methods: We searched the MEDLINE and Cochrane databases using the following key words: stent, acute myocardial infarction, abciximab and randomized trial. Four studies (ISAR-2, ADMIRAL, CADILLAC and ACE) were included in this analysis. The incidence of the individual end points of death, reinfarction and target vessel revascularization (TVR) at 30 days and at long-term follow-up was extracted. Follow-up data was available at 1 year for ACE and CADILLAC, at 3 years for ADMIRAL and 5 years for ISAR-2. A random effects model was used to calculate the combined odds ratio (OR) of reinfarction, TVR and mortality associated with the use of abciximab. Results: The 4 trials enrolled 2137 patients of whom 1074 were randomized to abciximab and 1063 to placebo. Long-term follow up was available for 2107 patients, 1064 in the abciximab group and 1043 in the control group. At 30 days, abciximab resulted in a significant reduction in the odds of TVR (OR 0.45, 95% CI, 0.27–0.75, P=0.003) and a non-significant reduction in the odds of reinfarction (OR 0.43, 95% CI, 0.18–1.0, P=0.06) but no reduction in 30-day mortality (OR 0.78, 95% CI, 0.47–1.2, P=0.34). During long-term follow up, abciximab treatment resulted in a non-significant reduction in the risk of TVR (OR 0.77, 95% CI 0.58–1.0, P=0.06) but no reduction in reinfarction (OR 0.58, 95% CI, 0.3–1.1, P=0.12) or mortality (OR 0.90, 95% CI, 0.48–1.6, P=0.74). Conclusions: Abciximab resulted in a significant reduction in TVR at 30 days that diminished over time. We were unable to demonstrate a significant reduction in reinfarction or mortality at 30 days or at 1–5 years. These results suggest the need for an appropriately powered clinical trial to define the role of abciximab during primary stenting for AMI.

Sign in / Sign up

Export Citation Format

Share Document